While long COVID is slowly becoming more understood, ordinary COVID-19 patients are experiencing lasting effects - scientists discovered that 76% of people have atleast one recurring symptom, six months after the original illness.
Two divisions of Active Care Group – Christchurch Group and Remeo – discuss the importance of infection prevention and control in the healthcare sector in light of COVID-19.
As of midnight tonight (20 December), London and the South East will enter strict Tier 4 restrictions - which includes no household mixing over Christmas, and no commuting to work.
SureWash, a CPD certified hand hygiene training company has been helping healthcare facilities globally with the fight against COVID-19. Founder and CTO, Dr Gerard Lacey tells us about their technology and what comes next for the company.
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.
Ann G. Matthysse, Professor of Biology from The University of North Carolina at Chapel Hill, shares her expertise on the transmission of Diarrheagenic E. coli by plants.
Dr Jeremy Aroles explores the implications of COVID-19 technologies, and proposes three ways to ensure that these powers can't be abused by the Government.
While diabetes has been declared as a signifier for infection complications, researchers now say that data suggests it is three times as likely these individuals have severe COVID or are hospitalised.
